OpenLegislation

Paragraph 13C Contact via NHS.net Connect and the Central Alerting SystemF1F8

Changes not yet applied. Later legislation changes this provision in ways not yet written into the text below:

(1)

An LPS chemist (C) must ensure that pharmacy staff at listed premises (including locums) have access to, and are able to send and receive F2messages via NHS.net Connect from, a premises specific F3NHS.net Connect account.

(2)

C must ensure that at least two members of the pharmacy staff have live, linked F4NHS.net Connect accounts to the premises specific NHS.net Connect account (unless fewer than two members of the pharmacy staff are engaged in the provision of NHS services).

(3)

As regards the Central Alerting System (CAS) operated by the Medicines and Healthcare products Regulatory Agency (MHRA)—

(a)

C must register C’s premises specific F5NHS.net Connect address with MHRA as an address at which C is content to accept notifications as part of the CAS (unless they are content with the address already in the system);

(b)

if C changes C’s premises specific F6NHS.net Connect address, P must immediately notify MHRA of C’s new premises specific NHS.net Connect address, in accordance with paragraph (a); and

(c)

C must monitor C’s premises specific F7NHS.net Connect account with sufficient frequency to ensure the safe and effective supply of medicinal products at or from C’s pharmacy premises, and must act on the alerts C receives as part of the CAS, as appropriate.

Annotations

Textual amendments

F1

Sch. 7 paras. 13B, 13C inserted (9.11.2020) by The National Health Service (Charges and Pharmaceutical and Local Pharmaceutical Services) (Amendment) Regulations 2020 (S.I. 2020/1126), regs. 1(2), 28

F2

Words in Sch. 7 para. 13C(1) substituted (1.10.2025) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Miscellaneous Amendments) Regulations 2025 (S.I. 2025/989), regs. 1(2), 66(2)(b)(i)

F3

Words in Sch. 7 para. 13C(1) substituted (1.10.2025) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Miscellaneous Amendments) Regulations 2025 (S.I. 2025/989), regs. 1(2), 66(2)(b)(ii)

F4

Words in Sch. 7 para. 13C(2) substituted (1.10.2025) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Miscellaneous Amendments) Regulations 2025 (S.I. 2025/989), regs. 1(2), 66(2)(c)

F5

Words in Sch. 7 para. 13C(3)(a) substituted (1.10.2025) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Miscellaneous Amendments) Regulations 2025 (S.I. 2025/989), regs. 1(2), 66(2)(d)(i)

F6

Words in Sch. 7 para. 13C(3)(b) substituted (1.10.2025) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Miscellaneous Amendments) Regulations 2025 (S.I. 2025/989), regs. 1(2), 66(2)(d)(ii)

F7

Words in Sch. 7 para. 13C(3)(c) substituted (1.10.2025) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Miscellaneous Amendments) Regulations 2025 (S.I. 2025/989), regs. 1(2), 66(2)(d)(iii)

F8

Words in Sch. 7 para. 13C heading substituted (1.10.2025) by The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Miscellaneous Amendments) Regulations 2025 (S.I. 2025/989), regs. 1(2), 66(2)(a)